New technique for breast cancer treatment and prevention-injection via nipple

JoVE, the Journal of Visualized Experiments, will publish a new technique for breast cancer treatment and prevention-injection of therapeutics via the nipple. The procedure, demonstrated on mice, offers direct access to the most common origin of breast cancer, the milk ducts, and could be used to offer cancer therapy that spares healthy regions of the body.

"Local delivery of therapeutic agents into the breast, through intra-nipple injection, could diminish the side effects typically observed with systemic chemotherapy-where the toxic drugs pass through all of the tissues of the body," said Dr. Silva Krause, one of the researchers behind the experiment, "It also prevents drug breakdown by the liver, for example, which can rapidly reduce effective drug levels."

According to Krause, she and her colleagues have already begun experimentation in applying the method. "The authors have utilized this technique to inject a new nanoparticle-based therapeutic that inhibits a specific gene that drives breast cancer formation," said Krause, "This targeted treatment was shown to prevent cancer progression in mice that spontaneously develop mammary tumors, [and] is currently in review in Science Translational Medicine."

In order to better communicate their procedure, Krause and her colleagues decided to publish with JoVE. "Because the reader can actually watch the process and see how reagents, instruments, and animals are physically handled over time, the likelihood of reproducing this method in their own labs is greatly enhanced," Krause said. "We believe this will help spread this new technical capability to many labs who are carrying out breast cancer research."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Assessing the impact of gozetotide in PSMA-positive prostate cancer